Bharat Biotech Bets on Vaccines to Tackle Drug Resistance

Bharat Biotech is pushing into a new frontier by using vaccines to tackle drug resistance, marking a strategic shift as the pandemic fades and antimicrobial resistance (AMR) rises as a global health threat.

The Hyderabad?based biotech, best known for its COVID?19 vaccine Covaxin, revealed that it is now developing vaccines specifically aimed at preventing drug?resistant infections that are increasingly common in hospital settings where antibiotics fail.

The company said its new vaccine strategy focuses on preventative shots that could be given before surgeries to block hospital?acquired infections, especially those fueled by drug?resistant pathogens. This approach reflects a broader industry pivot toward prevention rather than treatment as AMR escalates worldwide.

Also Read: Advancing Interventional Radiology in India Through Collaboration

Raches Ella, Bharat Biotech’s chief development officer, underscored the urgency of this shift, saying the company’s pipeline is expanding beyond traditional vaccines into areas where current drugs are losing effectiveness. Ella noted that vaccines designed to reduce dependency on antibiotics are central to tackling the challenge of antimicrobial resistance, which the company sees as a growing burden on health systems globally.

Alongside this new focus, Bharat Biotech continues to advance several late?stage vaccine candidates, including options targeting diseases such as tuberculosis, diarrheal illnesses, and other infections where drug resistance is a concern. These efforts aim to strengthen the company’s position in global public health by preventing illnesses that increasingly evade antibiotic treatments.

The company is also investing in future technologies, exploring advanced cell and gene therapies to support long?term growth while leveraging its vaccine expertise. This dual strategy keeps vaccine?based solutions for drug resistance at the heart of Bharat Biotech’s post?COVID expansion plan.